Total Payments
$436,431
2024 Payments
$50,282
Companies
37
Transactions
1,034
Medicare Patients
3,082
Medicare Billing
$699,955
Payment Breakdown by Category
Other$335,265 (76.8%)
Travel$67,783 (15.5%)
Food & Beverage$24,253 (5.6%)
Consulting$8,878 (2.0%)
Education$253.28 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $327,565 | 176 | 75.1% |
| Travel and Lodging | $67,783 | 219 | 15.5% |
| Food and Beverage | $24,253 | 622 | 5.6% |
| Consulting Fee | $8,878 | 6 | 2.0% |
| Honoraria | $7,700 | 3 | 1.8% |
| Education | $253.28 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $332,232 | 554 | $0 (2024) |
| Keryx Biopharmaceuticals, Inc. | $32,063 | 73 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22,790 | 33 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $11,412 | 75 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $11,156 | 44 | $0 (2024) |
| Horizon Therapeutics plc | $10,636 | 37 | $0 (2023) |
| Amgen Inc. | $10,525 | 44 | $0 (2024) |
| Vifor Pharma, Inc. | $1,595 | 7 | $0 (2024) |
| Lilly USA, LLC | $985.28 | 5 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $732.88 | 46 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $50,282 | 101 | Boehringer Ingelheim Pharmaceuticals, Inc. ($22,693) |
| 2023 | $65,217 | 136 | AstraZeneca Pharmaceuticals LP ($52,564) |
| 2022 | $57,702 | 142 | AstraZeneca Pharmaceuticals LP ($56,741) |
| 2021 | $76,847 | 189 | AstraZeneca Pharmaceuticals LP ($75,990) |
| 2020 | $60,906 | 115 | AstraZeneca Pharmaceuticals LP ($59,342) |
| 2019 | $86,154 | 188 | AstraZeneca Pharmaceuticals LP ($71,384) |
| 2018 | $38,648 | 121 | Keryx Biopharmaceuticals, Inc. ($32,024) |
| 2017 | $674.40 | 42 | Fresenius USA Marketing, Inc. ($152.54) |
All Payment Transactions
1,034 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: DIABETES | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $328.51 | General |
| Category: DIABETES | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $47.74 | General |
| Category: DIABETES | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: DIABETES | ||||||
| 11/06/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $14.34 | General |
| Category: NEPHROLOGY | ||||||
| 10/29/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $39.88 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $78.53 | General |
| Category: DIABETES | ||||||
| 10/10/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: Inflammation | ||||||
| 10/09/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/07/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: DIABETES | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $123.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $12.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $120.69 | General |
| Category: DIABETES | ||||||
| 09/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: DIABETES | ||||||
| 09/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $116.93 | General |
| Category: DIABETES | ||||||
| 09/13/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/05/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: DIABETES | ||||||
| 08/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $146.37 | General |
| Category: DIABETES | ||||||
| 08/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $106.54 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 590 | 3,777 | $571,856 | $158,285 |
| 2022 | 12 | 711 | 1,397 | $548,175 | $153,919 |
| 2021 | 14 | 819 | 2,824 | $634,424 | $193,361 |
| 2020 | 11 | 962 | 1,798 | $720,444 | $194,390 |
Total Patients
3,082
Total Services
9,796
Medicare Billing
$699,955
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 42 | 234 | $212,086 | $62,915 | 29.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 148 | 348 | $89,857 | $31,167 | 34.7% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 13 | 2,500 | $53,833 | $14,770 | 27.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 95 | 99 | $49,571 | $12,261 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 219 | $71,832 | $10,964 | 15.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 71 | 143 | $26,196 | $7,781 | 29.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 16 | 38 | $26,883 | $6,178 | 23.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 18 | 28 | $21,006 | $5,868 | 27.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 94 | $16,892 | $5,648 | 33.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 74 | $3,700 | $734.14 | 19.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 42 | 164 | $148,641 | $44,021 | 29.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 152 | 358 | $92,439 | $27,566 | 29.8% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 12 | 81 | $60,696 | $18,738 | 30.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 104 | 107 | $53,577 | $15,476 | 28.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 124 | 211 | $37,917 | $11,232 | 29.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 87 | 185 | $33,890 | $10,202 | 30.1% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 31 | 49 | $36,760 | $10,117 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 105 | 151 | $49,528 | $7,633 | 15.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 13 | 22 | $15,564 | $3,593 | 23.1% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 16 | 44 | $9,557 | $2,837 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $5,523 | $1,506 | 27.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $4,083 | $997.84 | 24.4% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 47 | 234 | $197,291 | $62,169 | 31.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 136 | 139 | $70,338 | $20,627 | 29.3% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 15 | 84 | $56,711 | $17,852 | 31.5% |
About Dr. Mohit Ahuja, M.D
Dr. Mohit Ahuja, M.D is a Nephrology healthcare provider based in Flowood, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1134339286.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohit Ahuja, M.D has received a total of $436,431 in payments from pharmaceutical and medical device companies, with $50,282 received in 2024. These payments were reported across 1,034 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($327,565).
As a Medicare-enrolled provider, Ahuja has provided services to 3,082 Medicare beneficiaries, totaling 9,796 services with total Medicare billing of $699,955. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Flowood, MS
- Active Since 05/23/2007
- Last Updated 06/16/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1134339286
Products in Payments
- LOKELMA (Drug) $276,395
- FARXIGA (Drug) $55,306
- Auryxia (Drug) $32,259
- JARDIANCE (Drug) $23,776
- KRYSTEXXA (Biological) $16,757
- AURYXIA (Drug) $10,960
- JYNARQUE (Drug) $10,226
- Veltassa (Drug) $1,765
- SAMSCA (Drug) $1,187
- ACTHAR (Biological) $607.21
- Velphoro (Drug) $586.90
- Parsabiv (Biological) $322.18
- Kerendia (Drug) $198.02
- LUPKYNIS (Drug) $146.99
- PURIFIED CORTROPHIN GEL (Drug) $125.41
- TARPEYO (Drug) $109.09
- BENLYSTA (Biological) $105.80
- RAYALDEE (Drug) $101.79
- TAVNEOS (Drug) $92.41
- HETLIOZ (Drug) $89.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Flowood
Francis Phillippi, Md, MD
Nephrology — Payments: $7,028
Nephrology $7,028
Dr. Steven Wagner, M.d, M.D
Nephrology — Payments: $6,848
Nephrology $6,848
Dr. Daphne Bilbrew, Md, MD
Nephrology — Payments: $6,370
Nephrology $6,370
Dr. Derrick Tesseneer, M.d, M.D
Nephrology — Payments: $6,056
Nephrology $6,056
Ami Patel, Md, MD
Nephrology — Payments: $5,086
Nephrology $5,086
Dr. Lee Ferguson, M.d, M.D
Nephrology — Payments: $5,068
Nephrology $5,068